Results 151 to 160 of about 7,559,498 (434)

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

New England Journal of Medicine, 2011
We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen ...
D. Porter, B. Levine, M. Kalos, A. Bagg, C. June   +4 more
semanticscholar   +1 more source

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

Chemical sensing by cell-surface chemoreceptor arrays: the roles of receptor cooperativity and adaptation [PDF]

arXiv, 2012
Most sensory cells use cross-membrane chemoreceptors to detect chemical signals in the environment. The biochemical properties and spatial organization of chemoreceptors play important roles in achieving and maintaining sensitivity and accuracy of chemical sensing.
arxiv  

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

INHIBITORY INTERACTION OF RECEPTOR UNITS IN THE EYE OF LIMULUS [PDF]

, 1957
H. K. Hartline, Floyd Ratliff
openalex   +1 more source

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Nature, 2020
J. Lan, J. Ge, Jinfang Yu, S. Shan, Huan Zhou, S. Fan, Qi Zhang, Xuanling Shi, Qisheng Wang, Linqi Zhang, Xinquan Wang   +10 more
semanticscholar   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody [PDF]

, 2010
<b>BACKGROUND:</b> In the acute phase of infection with feline immunodeficiency virus (FIV), the virus targets activated CD4+ T cells by utilising CD134 (OX40) as a primary attachment receptor and CXCR4 as a co-receptor.
A Bjorndal, A de Parseval, A de Parseval, A de Parseval, A Lauren, A McKnight, A McKnight, A Samman, AA Nabatov, AG Dalgleish, Ayman Samman, BJ Willett, BJ Willett, BJ Willett, BJ Willett, BJ Willett, BJ Willett, BJ Willett, BJ Willett, BJ Willett, BJ Willett, Brian J Willett, Brian J Willett, CD Ackley, CM Cheney, CM Kitchen, D Klatzmann, EA Berger, ED Quakkelaar, EE Sparger, EH Stalmeijer, Elizabeth L McMonagle, EM Poeschla, G Alkhatib, G Pancino, G Scarlatti, GA Dean, H Deng, HF Egberink, J Richardson, JJ Callanan, JJ Callanan, JK Murray, JK Yamamoto, JT Kimata, KHJ Siebelink, M Bendinelli, M Bendinelli, M Kraase, M Shimojima, M Torten, Margaret J Hosie, Martin Kraase, MJ Hosie, MJ Hosie, MJ Hosie, NC Pedersen, NC Pedersen, Nicola Logan, PJ Maddon, QX Hu, R Shankarappa, RB Dubridge, RI Connor, RI Connor, RV English, S Giannecchini, S Tasca, SM Philpott, T Dragic, TM Miyazawa, WS Pear, Y Feng   +72 more
core   +2 more sources

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

THE NATURE OF THE VIRUS RECEPTORS OF RED CELLS [PDF]

, 1948
George K. Hirst
openalex   +1 more source